The RADAR II [Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence] Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for mCRPC based on available data and clinical experience.
A consensus was developed to address important questions on mCRPC patient management.
In the absence of large scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action. Urology (2017), http://dx.doi.org/doi: 10.1016/j.urology.2016.12.033.
E. David Crawford, Daniel P. Petrylak, Neal Shore, Fred Saad, Susan F. Slovin, Nicholas J. Vogelzang, Thomas E. Keane, Phillip J. Koo, Leonard G. Gomella, Joe M. O'Sullivan, Bertrand Tombal, Raoul S. Concepcion, Paul Sieber, Nelson N. Stone, Steven E. Finkelstein, Evan Y. Yu.
More on the Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence] Working Group
Read Related Content: EAU 2017 - “Controversies in Metastatic Prostate Cancer”
Read Related Content: Everyday Urology - Oncology Insights Volume 1 Issue 2 "Bone Metastases and Mortality in Prostate Cancer: Can We Be Doing More?" by Neal Shore
Watch video with E. David Crawford and Philip Koo on - "Detection of Metastatic Disease: Review of the RADAR Group Recommendations."
Read Related Content: RADAR I - Beyond the Abstract by Philip Koo
Access abstract or full text article.